Hydrochloride pioglitazone decreases urinary monocyte chemoattractant protein-1 excretion in type 2 diabetics

Diabetes Research and Clinical Practice

Volumn 88, Issue 3, 2010, Pages 247-251

  Ye, Shandong ^a   Zheng, Mao ^a   Hu, Yuanyuan ^a   Fengzhen, Wu ^a   Zhao, Lili ^a   Chen, Yan ^a  

^a ANHUI PROVINCIAL HOSPITAL   (China)

Author keywords

Diabetic nephropathy; Monocyte chemoattractant protein 1; Pioglitazone

Indexed keywords

ACARBOSE; ALBUMIN; CREATININE; HEMOGLOBIN A1C; METFORMIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PIOGLITAZONE; SULFONYLUREA; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG MECHANISM; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; IN VIVO STUDY; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION; DIABETIC NEPHROPATHY; METABOLISM; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME; URINE;

ADULT; AGED; CHEMOKINE CCL2; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 78349265785     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2010.03.008     Document Type: Article

References (24)

1. Toblli J.E., Ferrini M.G., Cao G., Vernet D., Angerosa M., Gonzalez-Cadavid N.F. Antifibrotic effects of pioglitazone on the kidney in a rat model of type 2 diabetes mellitus. Nephrol. Dial. Transpl. 2009, 24:2349-2384.
2. Katavetin P., Eiam-Ong S., Suwanwalaikorn S. Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy. J. Med. Assoc. Thai 2006, 89:170-177.
3. Yang J., Zhang D., Li J., Zhang X., Fan F., Guan Y. Role of PPARγ in renoprotection in Type 2 diabetes, molecular mechanisms and therapeutic potential. Clin. Sci. 2009, 116:17-26.
4. Han S.Y., Kim C.H., Kim H.S., Jee Y.H., Song H.K., Lee M.H., et al. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J. Am. Soc. Nephrol. 2006, 17:1362-1372.
5. Wada T., Furuichi K., Sakai N., Iwata Y., Yoshimoto K., Shimizu M., et al. Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. Kidney Int. 2000, 58:1492-1499.
6. Tesch G.H. MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am. J. Physiol. Renal Physiol. 2008, 294:F697-F701.
7. Takebayashi K., Matsumoto S., Aso Y., Inukai T. Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. J. Clin. Endocrinol. Metab. 2006, 91:2214-2217.
8. Amann B., Tinzmann R., Angelkort B. ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1. Diabetes Care 2003, 26:2421-2425.
9. Ogawa S., Kobori H., Ohashi N., Urushihara M., Nishiyama A., Mori T., et al. Angiotensin II type 1 receptor blockers reduce urinary angiotensinogen excretion and the levels of urinary markers of oxidative stress and inflammation in patients with type 2 diabetic nephropathy. Biomark Insights 2009, 23(4):97-102.
10. Zheng M., Ye S. Monocyte chemoattractant protein-1 and diabetic nephropathy. Int. J. Pathol. Clin. Med. 2007, 27:253-256.
11. Saragidis P.A., Bakris G.L. Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int. 2006, 70:1223-1233.
12. Dalla Vestra M., Mussap M., Gallina P., Bruseghin M., Cernigoi A.M., Saller A., et al. Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes. J. Am. Soc. Nephrol. 2005, 16:S78-82.
13. Kikuchi Y., Imakiire T., Yamada M., Saigusa T., Hyodo T., Hyodo N., et al. Mizoribine reduces renal injury and macrophage infiltration in non-insulin-dependent diabetic rats. Nephrol. Dial. Transpl. 2005, 20:1573-1581.
14. Zheng M., Ye S., Zhai Z., Chen Y., Li X., Yang G., et al. Rosiglitazone protects diabetic rats against kidney disease through the suppression of renal monocyte chemoattractant protein-1 expression. J. Diabetes Complications 2009, 23:124-129.
15. Cooper M.E. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998, 352:213-219.
16. Banba N., Nakamura T., Matsumura M., Kuroda H., Hattori Y., Kasai K. Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy. Kidney Int. 2000, 8:684-690.
17. Chappey O., Dosquet C., Wautier M.P., Wautier J.L. Advanced glycation end products, oxidant stress and vascular lesions. Eur. J. Clin. Invest. 1997, 7:97-108.
18. Ruiz-Ortega M., Bustos C., Hernández-Presa M.A., Lorenzo O., Plaza J.J., Egido J. Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-kappa B activation and monocyte chemoattractant protein-1 synthesis. J. Immunol. 1998, 61:430-439.
19. Chow F., Ozols E., Nikolic-Paterson D.J., Atkins R.C., Tesch G.H. Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int. 2004, 65:116-128.
20. Chow F.Y., Nikolic-Paterson D.J., Atkins R.C., Tesch G.H. Macrophages in streptozotocin-induced diabetic nephropathy: potential role in renal fibrosis. Nephrol. Dial. Transpl. 2004, 19:2987-2996.
21. Bao Y., Jia R.H., Yuan S J., LI J. Rosiglitazone ameliorates diabetic nephropathy by inhibiting reactive oxygen species and its downstream-signaling pathways. Pharmacology 2007, 80:57-64.
22. Gruden G., Setti G., Hayward A., Sugden D., Duggan S., Burt D., et al. Mechanical stretch induces monocyte chemoattractant activity via an NF-kappaB-dependent monocyte chemoattractant protein-1-mediated pathway in human mesangial cells: inhibition by rosiglitazone. J. Am. Soc. Nephrol. 2005, 16:688-696.
23. Zafiriou S., Stanners S.R., Polhill T.S., Poronnik P., Pollock C.A. Pioglitazone increases renal tubular cell albumin uptake but limits proinflammatory and fibrotic responses. Kidney Int. 2004, 65:1647-1653.
24. Chua D.C., Bakris G.L. Is proteinuria a plausible target of therapy?. Curr. Hypertens. Rep. 2004, 6:177-181.